Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Klinger

Showing results (261-270 of 274) with videos related to

Pageof 28
Sort By:
American Journal of Respiratory and Critical Care Medicine|December 15, 2015
Higher Estradiol and Lower Dehydroepiandrosterone-Sulfate Levels Are Associated with Pulmonary Arterial Hypertension in MenCorey E Ventetuolo, Grayson L Baird, R Graham Barr, et al.
Biorxiv : the Preprint Server for Biology|June 4, 2026
Identification of drug candidates for rescue of SOX17 gene targets in pulmonary arterial hypertensionEleni Vasilaki, Bedia Akosman, Shanshan Song, et al.
JCI Insight|August 11, 2022
Chitinase 3 like 1 contributes to the development of pulmonary vascular remodeling in pulmonary hypertensionXiuna Sun, Erika Nakajima, Carmelissa Norbrun, et al.
The European Respiratory Journal|November 27, 2020
EmPHasis-10 as a measure of health-related quality of life in pulmonary arterial hypertension: data from PHARMarissa Borgese, David Badesch, Todd Bull, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
The Liver is an Inflammatory Mediator of Pulmonary Arterial HypertensionNavneet Singh, Jordan Lawson, Ashok Ragavendran, et al.
Comprehensive Physiology|May 15, 2026
Exploring the Lung-Liver Axis in Pulmonary Arterial HypertensionNavneet Singh, Jordan Lawson, Ashok Ragavendran, et al.
Journal of Critical Care|April 15, 2014
Heparin-induced thrombocytopenia in the critically ill: interpreting the 4Ts test in a randomized trialMark Crowther, Deborah Cook, Gordon Guyatt, et al.
Pulmonary Circulation|May 6, 2022
Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguatFranck F Rahaghi, Vijay P Balasubramanian, Robert C Bourge, et al.
The European Respiratory Journal|June 30, 2018
Lower DHEA-S levels predict disease and worse outcomes in post-menopausal women with idiopathic, connective tissue disease- and congenital heart disease-associated pulmonary arterial hypertensionGrayson L Baird, Christine Archer-Chicko, R Graham Barr, et al.
The Lancet. Respiratory Medicine|March 27, 2021
Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trialMarius M Hoeper, Hikmet Al-Hiti, Raymond L Benza, et al.
Pageof 28

Showing results (261-270 of 274) with videos related to

Sort By:
Pageof 28
American Journal of Respiratory and Critical Care Medicine|December 15, 2015
Higher Estradiol and Lower Dehydroepiandrosterone-Sulfate Levels Are Associated with Pulmonary Arterial Hypertension in MenCorey E Ventetuolo, Grayson L Baird, R Graham Barr, et al.
Biorxiv : the Preprint Server for Biology|June 4, 2026
Identification of drug candidates for rescue of SOX17 gene targets in pulmonary arterial hypertensionEleni Vasilaki, Bedia Akosman, Shanshan Song, et al.
JCI Insight|August 11, 2022
Chitinase 3 like 1 contributes to the development of pulmonary vascular remodeling in pulmonary hypertensionXiuna Sun, Erika Nakajima, Carmelissa Norbrun, et al.
The European Respiratory Journal|November 27, 2020
EmPHasis-10 as a measure of health-related quality of life in pulmonary arterial hypertension: data from PHARMarissa Borgese, David Badesch, Todd Bull, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
The Liver is an Inflammatory Mediator of Pulmonary Arterial HypertensionNavneet Singh, Jordan Lawson, Ashok Ragavendran, et al.
Comprehensive Physiology|May 15, 2026
Exploring the Lung-Liver Axis in Pulmonary Arterial HypertensionNavneet Singh, Jordan Lawson, Ashok Ragavendran, et al.
Journal of Critical Care|April 15, 2014
Heparin-induced thrombocytopenia in the critically ill: interpreting the 4Ts test in a randomized trialMark Crowther, Deborah Cook, Gordon Guyatt, et al.
Pulmonary Circulation|May 6, 2022
Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguatFranck F Rahaghi, Vijay P Balasubramanian, Robert C Bourge, et al.
The European Respiratory Journal|June 30, 2018
Lower DHEA-S levels predict disease and worse outcomes in post-menopausal women with idiopathic, connective tissue disease- and congenital heart disease-associated pulmonary arterial hypertensionGrayson L Baird, Christine Archer-Chicko, R Graham Barr, et al.
The Lancet. Respiratory Medicine|March 27, 2021
Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trialMarius M Hoeper, Hikmet Al-Hiti, Raymond L Benza, et al.
Pageof 28